
Jesse G Dixon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5559931/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood, 2020, 135, 2041-2048.	0.6	158
2	Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1173-1178.	0.4	69
3	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology, 2018, 36, 2593-2602.	0.8	59
4	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	0.6	58
5	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood, 2022, 139, 1684-1693.	0.6	56
6	A phase 1 and randomized, placebo ontrolled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer, 2019, 125, 3790-3800.	2.0	51
7	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 400-407.	3.0	44
8	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 124-128.	1.0	37
9	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	3.0	25
10	Intraâ€CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Medicine, 2020, 9, 7935-7942.	1.3	19
11	Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology, 2019, 143, 573-581.	1.4	7
12	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database Journal of Clinical Oncology, 2017, 35, 3535-3535.	0.8	6
13	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 2022, 114, 60-67.	3.0	5
14	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database Journal of Clinical Oncology, 2019, 37, 3502-3502.	0.8	5
15	Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database Journal of Clinical Oncology, 2018, 36, 3603-3603.	0.8	4
16	End of induction positron emission tomography complete response (PETâ€CR) as a surrogate for progressionâ€free survival in previously untreated follicular lymphoma. British Journal of Haematology, 2022, 198, 333-337.	1.2	2
17	Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database Journal of Clinical Oncology, 2018, 36, 3601-3601.	0.8	0
18	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. Blood, 2019, 134, 2812-2812.	0.6	0